Atorvastatin calcium: FUTURE STUDIES(2)
Another end-point trial, Treat to New Targets (TNT), isde-signed to test whether additional benefit in cardiovascular risk reduction is achieved by treating CAD patients to target LDL-C levels below 2.6 mmol/L with atorvastatin (personal communication). This five-year worldwide study involving 8600 patients will be one of the largest outcome trials ever conducted with a cholesterol-lowering agent.
Atorvastatin is being investigated in other long term studies in patients with diabetes. In a four-year, double-blind, randomized, multicentre study, atorvastatin 10 mg/day is being assessed versus placebo in over 2000 patients with type II diabetes with or without previous MI . Efficacy assessments will include incidence rates of cardiovascular death, nonfatal MI, recanalization (eg, percutaneous transluminal coronary angioplasty [PTCA]), stroke and coronary artery bypass surgery. Another trial, Atorvastatin in Diabetes with Albuminuria (AIDA), is investigating the effectiveness of atorvastatin 20 mg/day versus placebo in patients with diabetes. This three-year, double-blind, randomized, placebo controlled study will comprise 600 dyslipidemic patients with type II diabetes with albuminuria but without CAD. The occurrence of cardiovascular events will be assessed. This study is expected to be completed in 2001.